Literature DB >> 16257479

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials.

Barbara E H Coupar1, Damian F J Purcell, Scott A Thomson, Ian A Ramshaw, Stephen J Kent, David B Boyle.   

Abstract

DNA prime and recombinant fowlpox virus (rFPV) boost vaccines were designed to express multiple HIV or SIV antigens for use in human clinical trials and in pre-clinical trials in macaques. Three sets of vaccines with matching HIV or SIV antigen sets, modified for vaccine safety considerations, were constructed and shown to express the relevant proteins. The rFPV vaccines with inserts at up to three sites, were stable on passage in chick cell culture, including during GMP manufacture of vaccines for human Phase I clinical trials. Cellular and humoral immunogenicity in mice was demonstrated using a DNA prime/rFPV boost and vaccinia virus challenge model. These data establish a preliminary safety and efficacy profile for these multigenic vaccines suggesting they are suitable for advanced development as candidate HIV vaccines.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16257479     DOI： 10.1016/j.vaccine.2005.09.044

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  20 in total

1.  Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.

Authors:  Caroline S Fernandez; Miranda Z Smith; C Jane Batten; Robert De Rose; Jeanette C Reece; Erik Rollman; Vanessa Venturi; Miles P Davenport; Stephen J Kent
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 2.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

3.  Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

Authors:  Robert De Rose; C Jane Batten; Miranda Z Smith; Caroline S Fernandez; Viv Peut; Scott Thomson; Ian A Ramshaw; Barbara E H Coupar; David B Boyle; Vanessa Venturi; Miles P Davenport; Stephen J Kent
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

4.  An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.

Authors:  Atchriya Hemachandra; Rebekah L Puls; Sunee Sirivichayakul; Stephen Kerr; Pattarawat Thantiworasit; Sasiwimol Ubolyam; David A Cooper; Sean Emery; Praphan Phanuphak; Anthony Kelleher; Kiat Ruxrungtham
Journal:  Hum Vaccin       Date:  2010-10-01

5.  A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

Authors:  Charani Ranasinghe; Fiona Eyers; John Stambas; David B Boyle; Ian A Ramshaw; Alistair J Ramsay
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

6.  Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

Authors:  Elke Jäger; Julia Karbach; Sacha Gnjatic; Antje Neumann; Armin Bender; Danila Valmori; Maha Ayyoub; Erika Ritter; Gerd Ritter; Dirk Jäger; Dennis Panicali; Eric Hoffman; Linda Pan; Herbert Oettgen; Lloyd J Old; Alexander Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-19       Impact factor: 11.205

7.  Genetic screen of a mutant poxvirus library identifies an ankyrin repeat protein involved in blocking induction of avian type I interferon.

Authors:  Stephen M Laidlaw; Rebecca Robey; Marc Davies; Efstathios S Giotis; Craig Ross; Karen Buttigieg; Stephen Goodbourn; Michael A Skinner
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

8.  LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.

Authors:  Armin Bender; Julia Karbach; Antje Neumann; Dirk Jäger; Salah E Al-Batran; Akin Atmaca; Eckhart Weidmann; Melina Biskamp; Sacha Gnjatic; Linda Pan; Eric Hoffman; Lloyd J Old; Alexander Knuth; Elke Jäger
Journal:  Cancer Immun       Date:  2007-10-19

9.  Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies.

Authors:  Matthew G Cottingham; Andre van Maurik; Manola Zago; Angela T Newton; Richard J Anderson; M Keith Howard; Jörg Schneider; Michael A Skinner
Journal:  Clin Vaccine Immunol       Date:  2006-07

10.  IL-13Rα2 Regulates the IL-13/IFN-γ Balance during Innate Lymphoid Cell and Dendritic Cell Responses to Pox Viral Vector-Based Vaccination.

Authors:  Zheyi Li; Sreeja Roy; Charani Ranasinghe
Journal:  Vaccines (Basel)       Date:  2021-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.